L

Labiana Health SA
MAD:LAB

Watchlist Manager
Labiana Health SA
MAD:LAB
Watchlist
Price: 4.7 EUR Market Closed
Market Cap: 33.9m EUR

Relative Value

The Relative Value of one LAB stock under the Base Case scenario is 8.94 EUR. Compared to the current market price of 4.7 EUR, Labiana Health SA is Undervalued by 47%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LAB Relative Value
Base Case
8.94 EUR
Undervaluation 47%
Relative Value
Price
L
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
2
vs Industry
87
Median 3Y
0.2
Median 5Y
0.2
Industry
2.6
Forward
0.5
vs History
15
vs Industry
Median 3Y
-12.6
Median 5Y
-15.1
Industry
21.6
Forward
11.6
vs History
2
vs Industry
47
Median 3Y
-9.1
Median 5Y
-10.9
Industry
16.5
vs History
vs Industry
Median 3Y
-5.5
Median 5Y
-6.2
Industry
22.5
vs History
2
vs Industry
16
Median 3Y
3.5
Median 5Y
3
Industry
2.3
vs History
2
vs Industry
89
Median 3Y
0.2
Median 5Y
0.2
Industry
2.9
Forward
0.4
vs History
2
vs Industry
87
Median 3Y
0.4
Median 5Y
0.4
Industry
5.5
vs History
15
vs Industry
51
Median 3Y
1.7
Median 5Y
1.5
Industry
13
Forward
2.9
vs History
6
vs Industry
46
Median 3Y
-9.3
Median 5Y
-10.8
Industry
16.6
Forward
4.7
vs History
2
vs Industry
42
Median 3Y
-9.6
Median 5Y
-11.3
Industry
15.8
vs History
2
vs Industry
Median 3Y
-3.7
Median 5Y
-4.4
Industry
19.1
vs History
6
vs Industry
74
Median 3Y
0.5
Median 5Y
0.5
Industry
1.9

Multiples Across Competitors

LAB Competitors Multiples
Labiana Health SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
ES
Labiana Health SA
MAD:LAB
32.9m EUR 0.5 36.4 2.9 4.6
US
Eli Lilly and Co
NYSE:LLY
971.9B USD 16.4 52.8 35.5 38
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
509.1B USD 5.5 20.3 16.6 21.5
CH
Roche Holding AG
SIX:ROG
252.3B CHF 4.1 26.8 11.5 13.4
UK
AstraZeneca PLC
LSE:AZN
208.5B GBP 4.8 29.7 108 158
CH
Novartis AG
SIX:NOVN
202.4B CHF 4.5 17.7 11.2 14.5
US
Merck & Co Inc
NYSE:MRK
249.5B USD 3.9 13.1 9.3 11.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.5 13.7 9.6 11.2
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
147B USD 2.3 15 7.6 10.4
P/E Multiple
Earnings Growth PEG
ES
L
Labiana Health SA
MAD:LAB
Average P/E: 25
36.4
212%
0.2
US
Eli Lilly and Co
NYSE:LLY
52.8
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.3
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.8
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.7
38%
0.8
CH
Novartis AG
SIX:NOVN
17.7
17%
1
US
Merck & Co Inc
NYSE:MRK
13.1
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.7
4%
3.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
15
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
ES
L
Labiana Health SA
MAD:LAB
Average EV/EBITDA: 399
2.9
21%
0.1
US
Eli Lilly and Co
NYSE:LLY
35.5
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.6
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.5
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108
10%
10.8
CH
Novartis AG
SIX:NOVN
11.2
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.3
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.6
2%
4.8
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
ES
L
Labiana Health SA
MAD:LAB
Average EV/EBIT: 1 710.5
4.6
36%
0.1
US
Eli Lilly and Co
NYSE:LLY
38
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.5
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.4
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158
23%
6.9
CH
Novartis AG
SIX:NOVN
14.5
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11.1
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
11.2
1%
11.2
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
8%
1.3